NCT00410930View on ClinicalTrials.gov

Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients

PHASE2TerminatedINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

November 30, 2005

Conditions

Allergy

Interventions

BIOLOGICAL

Subcutaneous immunotherapy - Recombinant birch pollen

Trial Locations (1)

67091

Pr Gabrielle PAULI, Strasbourg

Sponsors

Lead Sponsor

Stallergenes Greer

All Listed Sponsors

lead

Stallergenes Greer

INDUSTRY

NCT00410930 - Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients | Biotech Hunter | Biotech Hunter